LB005/#1605 Randomized, phase II/III study of pegylated liposomal doxorubicin, bevacizumab, and atezolizumab in platinum-resistant ovarian cancer (NRG-GY009): clinical outcomes by PD-L1 and T cell infiltration status
Roisin E. O’Cearbhaill,Dmitriy Zamarin,Michael W. Sill,Hoa Duong,Steven Waggoner,Rachel N. Grisham,Floor J. Backes,Robert S. Mannel,János L. Tanyi,Matthew A. Powell,Cara Mathews,Sharad Ghamande,Leah McNally,Alexander Olawaiye,David Bender,Linda Duska,Heather A. Lankes,Russell J. Schilder,Michael A. Bookman,Carol Aghajanian